Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
- Status
- RECRUITING
- Phase
- PHASE2
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
- Status
- TERMINATED
- Phase
- PHASE2
Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.
- Status
- UNKNOWN
- Phase
- N/A
Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
- Status
- UNKNOWN
- Phase
- PHASE4
Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
- Status
- TERMINATED
- Phase
- PHASE2
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE3
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
AZD6738 Plus Durvalumab in Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment
- Status
- TERMINATED
- Phase
- PHASE1
Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.
- Status
- COMPLETED
- Phase
- N/A
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3